MedTrace Logo

A Study of MGC028 in Participants With Advanced Solid Tumors

NCT06723236 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2026-04-27

No results posted yet for this study

Summary

The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9.

The main question the study aims to answer is:

* What types of side effects will participants experience when receiving MGC028?
* Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors?

Participants will

* Undergo screening procedures to determine eligibility
* Receive study treatments initially every 3 weeks.
* Have blood samples taken for routine and research tests
* Have other examinations to check heart and lung function, and general health status
* Be asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary.
* Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.

Conditions

Interventions

BIOLOGICAL

MGC028

MGC028 is an antibody-drug conjugate targeted against ADAM9.

Sponsors & Collaborators

Principal Investigators

  • Pepi Pencheva, M.D. · MacroGenics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-13
Primary Completion
2026-11-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06723236 on ClinicalTrials.gov